Akèy › Astrositòm › Massachusetts
Etid klinik pou Astrositòm nan Massachusetts
13 etid pou Astrositòm ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07215910Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04188535Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 1 a 21 · Tout sèks · Mizajou Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253Implantable Microdevice In Primary Brain Tumors
- Brigham and Women's Hospital, Boston
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2025 · NCT04135807The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- Massachusetts General Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 a 90 · Tout sèks · Mizajou Feb 28, 2024 · NCT06283927The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- Massachusetts General Hospital, Boston
Ap rekriteEtid obsèvasyon
Jiska laj 90 · Tout sèks · Mizajou Feb 22, 2024 · NCT06273176The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 a 90 · Tout sèks · Mizajou Feb 22, 2024 · NCT06118723Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.